StockNews.AI
PCRX
StockNews.AI
180 days

Pacira to Report 2024 Financial Results on Thursday February 27, 2025

1. PCRX to report Q4 and full-year 2024 earnings. Announcement after U.S. market close. 2. Live conference call and webcast scheduled with Q&A session. Details on pre-registration provided. 3. Company emphasizes innovative non-opioid therapies and advanced gene therapy pipeline. Continued research highlighted.

Earnings
-2.3%Current Return
VS
-2.13%S&P 500
$26.0402/20 08:07 AM EDTEvent Start
$25.4402/21 02:40 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

An earnings announcement is typical and likely to cause modest short-term volatility. Historical earnings reports often lead to transient price adjustments rather than lasting shifts.

How important is it?

Although routine, the release is crucial for setting expectations regarding future performance. The focus on innovative treatments adds extra significance for investors.

Why Short Term?

Earnings announcements usually impact immediate trading sentiment and volatility. Previous similar reports have triggered short-term price moves before reverting.

Related Companies

PARSIPPANY, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2024 financial results after the close of the U.S. markets on Thursday February 27, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call. About Pacira Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.

Related News